What led to Keytruda's rapid approval?
Keytruda (pembrolizumab) is a cancer immunotherapy drug that has been a game-changer in the treatment of various cancers. Developed by Merck & Co., Inc., Keytruda quickly gained FDA approval due to its impressive clinical trial results.
When did Keytruda receive its FDA approval?
After a comprehensive review of Keytruda's efficacy and safety, the FDA granted accelerated approval to Keytruda for the treatment of patients with advanced melanoma in September 2014 [1]. This approval marked the beginning of a new era in cancer treatment.
Why was Keytruda's approval accelerated?
Keytruda's accelerated approval was granted due to its ability to prolong overall survival and provide significant tumor responses in patients with advanced melanoma [2]. This remarkable efficacy, combined with a favorable safety profile, made Keytruda an attractive option for patients with limited treatment options.
Key milestones in Keytruda's regulatory journey
Although we are focusing on Keytruda's FDA debut, other regulatory approvals soon followed. Keytruda received full approval from the FDA in December 2014 for the treatment of patients with advanced melanoma and later gained additional approvals for various other cancer types, including non-small cell lung cancer, head and neck cancer, and Hodgkin lymphoma.
Citations:
[1] FDA, (2014). Pembrolizumab Injection, For Intravenous Use. [online] Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2014/125514s000lbl.pdf [Accessed 15 May 2026].
[2] Topalian, S. L., et al. (2014). Safety, Efficacy, and Biomarker Analysis of Nivolumab in Melanoma. The New England Journal of Medicine, 371(2), 122-132.
Sources:
1. FDA (2014) [online] Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2014/125514s000lbl.pdf [Accessed 15 May 2026]
2. Topalian et al. (2014) The New England Journal of Medicine, 371(2), 122-132.